Simultaneously, developing radiosensitizers tailored to genetic vulnerabilities (e.g., PARP inhibitors for SMAD4- or BRCA-mutant tumors, ATR inhibitors for ATM-overexpressing cancers) will expand therapeutic options. Here, PARP1 is linked to cancer.